Please login to the form below

BACE inhibitor

This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.

Merck acquires pre-clinical biotech Calporta for up to $576m

Merck, among many big pharma players, has had its fair share of failure in the neurodegenerative research area – its lead BACE inhibitor verubecestat failed to show a clinical effect in

Latest news

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category. In a potential final blow to the BACE inhibitor treatment category, Biogen and Eisai have discontinued trials of elenbecestat after the ... The sadly predictable pattern of the BACE
Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Novartis and Amgen researchers were well aware of these problems seen in earlier BACE inhibitor trials, but had not detected them in their own early trials. ... The loss of CNP520 leaves just one major BACE inhibitor standing – Eisai and Biogen’s
Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

The additional study could also include an arm combining BAN2401 with Eisai’s BACE inhibitor elenbecestat, a drug class that has also seen a string of failures in late-stage testing ... BACE inhibitors are designed to an enzyme involved in the
Eisai to tackle dementia in new US research facility

Merck &Co has also seen failure with its BACE1 inhibitor verubecestat, which also led to the drug’s abandonment. ... However Eisai, which also has a BACE inhibitor elenbecestat in late-stage testing, has several dementia candidates in its pipeline, and
Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom

Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

Deal Watch table for September 2014

525. AstraZeneca / Lilly. Licence and collaboration. Oral BACE inhibitor in phase I for Alzheimer's disease. ... TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies.
Pharma deals during September 2014

Rhizen to change their deal from a 50/50 joint venture to a global (excluding India) licence. The product, an oral PK13 delta inhibitor appears to have completed phase 2 the ... AstraZeneca and Lilly have announced a joint development and
Eisai: Bucking the trend with R&D growth

BACE inhibitor E2609.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....